ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNG Synairgen Plc

4.755
0.105 (2.26%)
23 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.105 2.26% 4.755 4.52 4.99 - 189,060 16:35:30
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.53 9.36M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.65p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.36 million. Synairgen has a price to earnings ratio (PE ratio) of -0.53.

Synairgen Share Discussion Threads

Showing 9326 to 9343 of 99175 messages
Chat Pages: Latest  379  378  377  376  375  374  373  372  371  370  369  368  Older
DateSubjectAuthorDiscuss
02/6/2020
19:27
>> amaretto

Are you referring to me or Sheedy?

nobbygnome
02/6/2020
19:27
Around 80 people have now absconded from this thread to the guild. The bliss of reasoned debate is palpable....
nobbygnome
02/6/2020
19:24
You guys can all request to enter now and I will let you in .
nobbygnome
02/6/2020
19:21
FOrgot, some dont like link clicks so:

June 2014

Shares in drug developer Synairgen (LON:SNG) shot up as it named pharma giant AstraZeneca (LON:AZN) as its new partner to develop its anti asthma drug.

The global exclusive licence agreement is for SNG001, which one broker described as having "blockbuster"potential.

Astra will pay the firm an upfront payment of US$7.25mln immediately.

There are development and commercial milestones totalling US$225mln and up to mid-teen royalties payable on sales.

AstraZeneca will be responsible for all future costs and early next year will kick off a Phase IIa study in patients with severe asthma, building on available clinical data from an initial Phase lla trial in a broad asthma population.

Richard Marsden, Synairgen chief executive, said: "We're delighted that this truly innovative programme, discovered at the University of Southampton and developed by Synairgen, will be taken forward by AstraZeneca.

"With its strong research focus and extensive experience in respiratory disease, AstraZeneca's commitment to developing novel medicines for patients with asthma and COPD makes them the ideal partner for SNG001."

Broker finnCap said: "With the deal encompassing the global asthma and COPD markets, we believe SNG001 has blockbuster potential. Although SNG001 will still have to pass through clinical development, we believe there is a lower risk of failure than other drugs at a similar stage of development. We estimate regulatory approval could be in 2021. We have re-visited our valuation, and raise our price target to 120p."

spartan attack
02/6/2020
19:17
In essence, its a retail punt...the 'lads' took advantage

ANd now its bye bye retail

haha

spartan attack
02/6/2020
19:04
I digress - lets bring it back to todays players later, and get into the real dirt

hahaha

spartan attack
02/6/2020
19:02
Hi. I would also like to continue seeing all sensible debate - would appreciate someone sending me the required coins if poss? Thanks in advance.
mavo1
02/6/2020
19:00
But what else did the Turkeys here not highlight?
spartan attack
02/6/2020
18:46
Now im not going into all data on peers. But this as most know , is the case. All same. No matter what their strategy, timing expectation and drug/therapy approach, they are all same. A global punt. Nothing unique to SNG expectation in market



Peer correlation same. But all at different stages and approaches
— Spartan Attack (@attack_spartan)

spartan attack
02/6/2020
18:41
Financials, no point wasting time on those. Its a one trick pony. Succeed on hospital home trial or bust.

What do funds do typically, when profits are up against this risk?


A one play bet. Even after placing. Boom Bust July/August
— Spartan Attack (@attack_spartan)

spartan attack
02/6/2020
18:33
We have a retail holding average in 2020 of 49.8p

An averaged down holding of 47.6p over last 14 days

And a fund average holding of 11.4p (not including 35p scrib)

.......................................

This is fairly standard in just about all stock positions and plays.

Ponder that and look at it from their perspective now

spartan attack
02/6/2020
18:32
I've been out all day - so only just catching up with the coins issue.
Having just tried to join 'The Guild', I am short of funds.

Could someone oblige please - Thanks in anticipation.

801710245
02/6/2020
18:23
I would very much be obliged to anyone who could spare some coins and if Nobbygnome would kindly let me join the guild. Have been most interested and grateful for all the information people provide, such a shame this board has been spoilt.
thomastatra
Chat Pages: Latest  379  378  377  376  375  374  373  372  371  370  369  368  Older

Your Recent History

Delayed Upgrade Clock